Human Papillomavirus

Phase I Study Of Topical Gel For Treatment Of Genital Warts Initiated

Published in TB and Outbreaks Week, October 9th, 2001

Origenix Technologies, Inc. announced that an investigational new drug application (IND) has been filed with the U.S. Food and Drug Administration (FDA) for ORI-1001, a topical gel for the treatment of genital warts caused by human papillomavirus (HPV) and that a Phase I clinical study has been initiated.

The Phase I clinical study is a single-center, randomized, double-blind placebo-controlled study to evaluate the safety of ORI-1001 Gel in 30 human volunteers during seven days of cutaneous application. Dr. Karl Beutner, MD and principal investigator for the Phase I study commented: "We look forward to beginning the clinical evaluation of this novel compound for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-10-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry